Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761451 | 0.75 | CYP19A1 (0.41) | CYP19A1LMNACHRM2CHRM3RAB9A | |
| SCHEMBL14806787 | 0.75 | CYP19A1 (0.35) | CYP19A1BACE1 | |
| SCHEMBL16177445 | 0.74 | AR (0.34) | ARRAB9ASMN1; SMN2 | |
| SCHEMBL12600976 | 0.73 | CHRM2 (0.52) | CYP19A1LMNACHRM2CHRM3AR | |
| SCHEMBL761687 | 0.72 | MEN1 (0.39) | CYP19A1BACE1MEN1KMT2A | |
| SCHEMBL838931 | 0.72 | LMNA (0.39) | CYP19A1LMNARAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2235681 | 0.72 | AR (0.33) | ARRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL17471625 | 0.72 | TSHR (0.42) | CYP19A1LMNACHRM2CHRM3BACE1 | |
| SCHEMBL8283007 | 0.70 | CHRM2 (0.41) | CYP19A1CHRM2CHRM3ARMEN1 | |
| SCHEMBL24862934 | 0.69 | CYP19A1 (0.42) | CYP19A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356370-B1 | 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-10981900-B2 | Spiro compound and use thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-02-13 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| US-9566312-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20150041052-A1 | WAVELENGTH CONVERSION LAYER ON A GLASS PLATE TO ENHANCE SOLAR HARVESTING EFFICIENCY | NITTO DENKO CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | NATIONAL TAIWAN UNIVERSITY (TW) | 2014-03-13 | — | — | US | disclosed |
| EP-1740578-B1 | 4- 2- (CYCLOALKYLAMINO) PYRIMIDIN-4-YL ] - (PHENYL) - IMIDAZOLIN-2- ONE DERIVATIVES AS P38 MAP- KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7700771-B2 | Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7700771-B2 | Heterocyclic compound which may be used as a medicine having p38 MAP kinase inhibitory activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20100087442-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087442-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2010-04-08 | — | — | US | disclosed |
| US-7655804-B2 | N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-7655804-B2 | N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | US | disclosed |
| US-7196085-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | S1PR1, S1PR2, S1PR3 | CYP19A1 1178/4885LMNA 2331/4885CHRM2 1563/4885 |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | CYP19A1 391/4885LMNA 1693/4885CHRM2 4694/4885 |
| US-20100087442-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | SERPINB1, CTSZ, ELANE | CYP19A1 1998/4885LMNA 4036/4885CHRM2 3064/4885 |
| US-20140073611-A1 | METHODS FOR DRUG SCREEN USING ZEBRAFISH MODEL AND THE COMPOUNDS SCREENED THEREFROM | PLOD3, MYOC, SLTM | CYP19A1 4720/4885LMNA 72/4885CHRM2 1996/4885 |
| US-10981900-B2 | Spiro compound and use thereof | S1PR1, S1PR2, S1PR3 | CYP19A1 1178/4885LMNA 2331/4885CHRM2 1563/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | CYP19A1 1018/4885LMNA 2696/4885CHRM2 655/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | CYP19A1 1303/4885LMNA 2491/4885CHRM2 480/4885 |
| US-20070185326-A1 | antiinflammatory agents; antiarthritic agents | MAPK1, CHUK, MAPK3 | CYP19A1 3359/4885LMNA 4585/4885CHRM2 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.